Abstract
Background: Atrial fibrillation (AF) is prevalent in patients with end-stage kidney disease. However, the role of oral anticoagulant therapy in patients undergoing dialysis is unclear owing to the propensity for increased bleeding. We evaluated the prevalence of AF and oral anticoagulant therapy and its association with mortality in patients undergoing dialysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
